Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is poised for success due to their strong pipeline and upcoming catalysts which include dose escalation results from Phase 1b trials evaluating their advanced programs targeting Nectin-4 and B7H3, clinical imaging and dosimetry assessment of AKY-2519, and commencement of IND-enabling studies for two earlier stage programs. While there are risks, such as negative clinical results and delays in advancing pipeline candidates, the company's market value of $1.93B and 12-month price target of $35 per share showcase its potential for significant growth.

Bears say

Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for a broad range of solid tumors, with a pipeline consisting of products such as AKY-1189 and AKY-2519. Despite positive imaging and dosimetry results for AKY-2519, negative financial results reported for 2025 and projected for 2026, including a net loss of $78.34 per share and R&D expenses of $67.5M, raise concerns about the company's ability to successfully advance its pipeline and obtain regulatory approvals in a timely manner. Additionally, competition in the RIT/RLT space and potential long-term dilution risk are significant risks for investors to consider.

AKTS has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 4 analysts, AKTS has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.